Martinsried/ Munich – Medigene AG (FSE: MDG1, Prime Standard) today announces its participation at the following upcoming scientific and investor conferences. Please note that all mentioned conferences will be conducted virtually due to COVID-19.
Cell Therapy Manufacturing & Gene Therapy Congress
Date: 19 – 22 October
Website: https://informaconnect.com/celltherapy/
TCR Therapies Summit
Date: 26 – 29 October
Website: https://tcr-therapies-summit.com/
BIO-Europe Digital
Date: 26 – 29 October
Website: https://informaconnect.com/bioeurope/?gclid=EAIaIQobChMIn-75yv7b6wIVFed3Ch27uAezEAAYASAAEgLuufD_BwE
Neoantigen Based Therapies Summit
Date: 3 – 5 November
Website: https://neo-antigen.com/
35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020)
Date: 9 – 14 November
Website: https://www.sitcancer.org/events/event-description?CalendarEventKey=bcb54b5c-c612-4e28-854f-0f8c41bca69f&Home=%2Fevents%2Fevent-description
62nd ASH Annual Meeting and Exposition
Date: 5 – 8 December
Website: https://www.hematology.org/meetings/annual-meeting
– end of announcement –
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.
For more information, please visit http://www.medigene.com
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Contact Medigene AG
Dr Gary Waanders, Dr Anna Niedl
Tel.: +49 89 2000 3333 01
email: investor@medigene.com